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INTRODUCTION
Secretion of thyroid-stimulating hormone (TSH) 
by the pituitary gland is stimulated by hypo-
thalamic TSH-releasing hormone (TRH) and 
inhibited by high serum levels of two hormones 
produced by the thyroid: tri-iodothyronine (T3) 
and tetraiodothyronine (T4, or thyroxine), which 
contain three and four atoms of iodine, respec-
tively. T4 acts at hypothalamic and pituitary 
levels after enzymatic local conversion into T3.
1,2 
Both T3 and T4 have two ENANTIOMERS; the 
l-enantiomers (l-T3 and l-T4) are responsible 
for their biologic effects.
Although T4 is the main hormone produced 
by the thyroid gland, T3 is the active thyroid 
hormone in many organs. The most impor-
tant pathway for T4 metabolism is its mono-
deiodination to active T3. This reaction is 
catalyzed by type 1 and type 2 deiodinases. Type 
1 deiodinase is highly expressed in human liver 
and kidney, and type 2 deiodinase is expressed in 
skeletal and cardiac muscles, the central nervous 
system and the pituitary gland (Figure 1).1,2 
Orally administered l-T4 (levothyroxine) is effi-
ciently converted to l-T3, thereby reproducing 
the pathway of endogenous T4 processing. Serum 
T3 levels remain stable after l-T4 adminis tration, 
but vary widely after oral administration of 
l-T3 (liothyronine);
3,4 this is why l-T4 has been 
the drug of choice for long-term treatment of 
thyroid cancer patients. Moreover, the administra-
tion of l-T4 is preferred because serum T4 is 
more effective as a regulator of TSH secretion 
than serum T3 is.
There is general agreement that all thyroid 
cancer patients should be treated with l-T4 after 
total thyroidectomy.5–7 This therapy has two 
objectives: hormone replacement (i.e. correc-
tion of surgically induced hypothyroidism) and 
hormone suppression (i.e. reduction of the serum 
level of TSH, which can stimulate the growth of 
persistent or recurrent neoplastic tissue). For 
years, life-long TSH suppression with exogenous 
l-T4 therapy was recommended in all guidelines 
for the postoperative management of thyroid 
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cancers, but more recently this strategy has been 
challenged. The change came about consequent 
to a better understanding of the adverse effects 
of l-T4 suppressive treatment and of the natural 
history of thyroid cancer, which raised the possi-
bility of a reliable diagnosis of cure in low-risk 
patients. Here we review the basic principles of 
l-T4 treatment for thyroid cancer and current 
indications for its use. Practical aspects such as 
dose calculation, adjustment for specific clinical 
situations, and side effects are discussed in the 
second part of the review.
RATIONALE FOR TREATMENT 
OF THYROID CANCER PATIENTS USING 
L-TETRAIODOTHYRONINE
Historical setting
The rationale for administering l-T4 therapy to 
patients with papillary or follicular thyroid carci-
nomas is based on evidence collected in numerous 
studies. In 1937, Dunhill8 reported the regres-
sion of papillary thyroid cancer in two patients 
treated with thyroid extracts. It was later demon-
strated that hypo thyroidism stimulates neoplastic 
thyroid-cell growth by increasing serum TSH 
levels.9,10 Indeed, administration of l-T4 (resulting 
in lower levels of TSH) had the beneficial effect 
of limiting tumor growth.11 Evidence supporting 
l-T4 treatment as an essential part of thyroid 
cancer management was provided by two retro-
spective investigations12,13 and one prospec-
tive,14 non-randomized study. In Mazzaferri 
and Jhiang’s12 retrospective analysis of 30 years 
of follow-up data, patients treated with l-T4 had 
25% fewer recurrences (30% versus 40%) and 
50% fewer cancer-related deaths (6% versus 12%) 
than those who did not receive l-T4 therapy and 
who had serum TSH levels within the hypothyroid 
range.12 Pujol et al.13 showed that thyroid-cancer 
patients with TSH levels that were consistently 
below 0.1 mU/l had an improved rate of relapse-
free survival compared with those whose TSH 
levels were always above 1.0 mU/l, and this effect 
was independent of age, gender, histology, and 
tumor stage. Finally, Cooper et al.14 showed 
that a lesser degree of TSH suppression was an 
independent predictor of progression in patients 
with high-risk (stage III or IV) papillary thyroid 
cancers, but not in those with low-risk tumors. 
When patients treated with radioiodine were 
included in the multivariate analysis, the influ-
ence of TSH suppression dropped to border-
line significance because radioiodine destroyed 
persistent neoplastic disease.
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Figure 1 Regulation of the pituitary–thyroid 
axis: the role of tri-iodothyronine and 
tetraiodothyronine in the feedback regulation of 
thyroid-stimulating hormone secretion. Secreted 
tetraiodothyronine must be converted to 
tri-iodothyronine to produce biologic effects. 
Type 1 deiodinase is produced in human liver, 
kidney and thyroid gland and these organs 
produce tri-iodothyronine in the serum. Type 2 
deiodinase is widely distributed in cardiac and 
skeletal muscle, thyroid gland, the central nervous 
system and the pituitary gland.1 The expression 
of type 2 deiodinase in the human heart suggests 
that cardiac tissue can respond to changes in 
serum tetraiodothyronine levels, as occurs in the 
pituitary gland. D1, type 1 deiodinase; D2, type 2 
deiodinase; SRIH, somatotrophin (somatostatin)-
release-inhibiting hormone; T3, tri-iodothyronine; 
T4, tetraiodothyronine; TRH, thyroid-stimulating 
hormone releasing hormone; TSH, thyroid-
stimulating hormone.
GLOSSARY
ENANTIOMERS
Organic molecules that are 
nonsuperimposable mirror 
images, existing in either the 
L-form or D-form
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The effects of thyroid-stimulating hormone 
on thyroid growth
Experimental studies conducted in vitro and 
in animal models have elucidated the scien-
tific basis for the above clinical observations. 
Thyroid-cell proliferation was shown to be TSH-
dependent.15 GOITROGENS, iodine deficiency, 
and partial thyroidectomy promote the develop-
ment of thyroid cancers, but these tumors can 
be prevented by the oral administration of l-T4 
or by hypophysectomy, both of which reduce or 
suppress TSH secretion.16
Differentiated tissue in papillary and follicular 
thyroid cancers has functional TSH receptors 
(TSHRs),17and thyroid cancer cells in PRIMARY 
CULTURE respond to TSH stimulation by acti-
vating the cyclic-AMP cascade that promotes cell 
growth.5,18,19 In contrast, expression of the TSHR 
(together with that of other thyroid-specific genes 
and proteins) is markedly decreased in poorly 
differentiated thyroid cancers.20–22 Enhanced 
growth of well-differentiated thyroid cancer 
cells can thus be anticipated when TSH produc-
tion is stimulated. This is consistent with the 
more extensive and aggressive disease observed 
in patients with Graves’ disease, who have 
TSHR-stimulating immunoglobulins.23,24
Based on these findings, TSH-suppressive 
therapy with l-T4 has become an integral 
part of the treatment of papillary and follic-
ular thyroid carcinomas; however, these data 
provide no indication of the optimal degree 
of suppression.
The effects of thyroid-stimulating hormone 
on thyroid-cell differentiation
Metastases from papillary or follicular thyroid 
cancers might retain several biologic functions 
fulfilled by normal thyrocytes, such as iodine 
uptake or the synthesis and secretion of thyro-
globulin (a specific thyroid glycoprotein used for 
hormone synthesis), but they are rarely capable 
of synthesizing thyroid hormones.21,22 The 
differentiation of neoplastic and normal thyroid 
cells (so that they take up iodine, and synthesize 
and secrete thyroglobulin), depends on TSH. 
Accordingly, no radioiodine uptake is seen when 
the patient is on l-T4 therapy. Uptake by meta-
stases occurs exclusively after TSH stimula tion, 
and even then it is observed in only two out of 
three patients with metastatic disease. In patients 
with persistent or recurrent disease, serum 
thyroglobulin concentrations increase following 
TSH stimulation whereas significant decreases 
(sometimes to undetectable levels) are observed 
during l-T4 therapy. This modulation is evident 
even when no radioiodine uptake is observed in 
the metastases. These observations confirm that 
TSH is capable of stimulating functional activity 
(and, consequently, growth) in most differenti-
ated thyroid carcinomas and that functional 
receptors for TSH are also present in metastases 
from these tumors.22
Features of thyroid cells that are 
independent of thyroid-stimulating hormone
Although TSH plays a major role in the regula-
tion of thyroid-cell differentiation and prolifera-
tion, there is a body of evidence supporting 
the view that thyroid-cell regulation involves 
a complex network of mechanisms, including 
some that are TSH-independent. Neoplastic 
thyroid-cell growth can thus be affected by 
growth factors such as epidermal growth 
factor,25 insulin-like growth factors,26 basic 
fibroblast growth factor, platelet-derived growth 
factor, and transforming growth factor-α, and by 
activated oncogenes including RET(PTC), BRAF 
and the RAS family.27
These biologic findings have been supported 
by clinical observations. One of the best models 
of ‘autonomous’ (i.e. TSH-independent) thyroid-
cell growth is the functioning ‘hot’ thyroid 
nodule. These nodules are frequently the result 
of activating mutations of the genes encoding the 
TSHR28 and the Gsα protein family, although these 
activations are rare in thyroid cancers.29,30 Low-
level TSH-independent secretion of T4 has been 
demonstrated in normal thyroid glands,31 which 
explains why higher doses of l-T4 are required 
to reduce TSH levels in hypo thyroid patients 
with thyroid cancer (when their thyroid glands 
have been totally ablated) than in those with 
benign disease, where at least some thyroid tissue 
remains functionally active.32 A TSH-independent 
mitogenic cascade might remain active in 
neoplastic thyroid cells, and might be retained, 
therefore, even when serum TSH is maintained 
at low levels with l-T4 treatment. This situation is 
most commonly observed in elderly patients with 
poorly differentiated thyroid carcinomas, which 
are probably characterized by an accumulation of 
genetic alterations.
OPTIMAL SUPPRESSION 
OF THYROID-STIMULATING HORMONE
As mentioned above, increasing knowledge 
about the adverse effects of suppressive doses 
GLOSSARY
GOITROGENS
Substances that induce the 
formation of a goiter
PRIMARY CULTURE
A cell or tissue culture made 
by direct transfer from the 
natural source to an artificial 
medium
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of l-T4 and about the natural history of thyroid 
cancer, which raised the possibility of a reliable 
diagnosis of cure in low-risk patients, caused 
some authors to challenge the universal use of 
suppressive therapy in thyroid cancer patients. In 
this context, two questions need to be addressed: 
what is the ideal serum level of TSH, and should 
the serum TSH be maintained at the same level 
in all thyroid cancer patients who receive l-T4?
What are optimal serum thyroid-stimulating 
hormone levels during thyroid cancer 
follow-up?
The concept of TSH-suppression therapy has 
changed over the years. From the initial empir-
ical suggestion that all thyroid cancer patients 
should be placed on lifelong l-T4 therapy with 
the highest tolerated dose, we now have reliable 
methods with which to assess the adequacy of 
suppressive doses of l-T4.
In the 1970s, the optimal l-T4 dose for 
TSH suppression was defined as the dose that 
ab olished TSH release from the pituitary in 
response to TRH; however, TSH assays were not 
sufficiently sensitive to detect values in the lower 
end of the reference range . In the 1980s, assay 
sensitivity improved, and serum TSH levels as 
low as 0.1 mU/l could be detected. Nonresponse 
to TRH was thus found to correspond to a basal 
serum TSH level below 0.1 mU/l and, conse-
quently, suppressive therapy was considered 
adequate only when the serum TSH level was 
below this detectable cut-off. Subsequent testing 
with ultra sensitive TSH assays, however, revealed 
that a high proportion of patients with levels in 
this range had subclinical thyrotoxicosis.
The goal of replacement therapy is to restore 
serum TSH to the reference range; however, the 
normal TSH range is a matter of controversy.33–36 
Overt thyrotoxicosis is reflected by a TSH level 
below 0.1 mU/l, with elevated levels of total 
and free (not bound to serum proteins) T3 
and T4. Although it is difficult to define a TSH 
level that establishes the presence of sub clinical 
thyro toxicosis, current studies suggest that 
values below 0.5 mU/l might be associated with 
increased cardiovascular mortality in elderly 
patients:37 in young and middle-aged patients 
the level of TSH suppression that eliminates 
the risk of subclinical thyrotoxicosis has yet to 
be defined. In studies conducted so far on the 
adverse effects of long-term l-T4 therapy, no 
attempt has been made to correlate these effects 
with serum TSH values.38
Although the reduction in serum levels of 
thyroglobulin associated with low TSH levels 
provides indirect evidence of the efficacy of TSH 
suppression, increasing the degree of suppression 
to produce serum TSH levels below 0.5 mU/l 
does not result in further decreases in serum 
thyroglobulin levels. This supports the hypoth-
esis that more aggressive TSH suppression might 
be of little benefit in terms of limiting tumor 
growth;32,39 however, these studies were based 
on small numbers of patients and cannot exclude 
a benefit resulting from complete suppression in 
patients with persistent disease.
Is suppressive L-tetraiodothyronine 
therapy always necessary?
As discussed above, several lines of evidence indi-
cate that suppressive l-T4 treatment decreases 
the risk of progression in patients with persis-
tent disease, and reduces the rates of recur-
rence and cancer-related-mortality in high-risk 
cancer patients. In other subgroups of thyroid 
cancer patients, however, the use of l-T4 therapy is 
not associated with any significant improvement 
in recurrence or survival rates.
A study designed to determine the effective-
ness of radioiodine scanning in detecting recur-
rence of thyroid cancer after thyroid ablation 
and the withdrawal of l-T4 after 12 months’ 
therapy showed that the long-term risk of recur-
rence was less than 1% in low-risk patients with 
no evidence of persistent disease—that is, in 
patients who had undergone complete resection 
of all neoplastic tissues at initial surgery, had no 
uptake outside the thyroid bed (as shown on the 
postablation whole body scan), had no sono-
graphic evidence of lymph adenopathy in the 
neck and had serum thyroglobulin levels that 
remained undetectable following TSH stimula-
tion at the 6–12 months’ follow-up appoint-
ment.38 Furthermore, all recurrences were 
limited to the neck lymph nodes and could 
thus be cured.40,41 These favorable results were 
obtained even though the majority of these 
patients presented with serum levels of TSH 
within the normal range.40,41 Indeed, these 
favorable results can hardly be improved with 
long-term suppressive treatment.
Therefore, within the first year after initial 
treatment with l-T4, it is possible to identify 
patients who show no evidence of disease and 
who have, consequently, no need for continued 
suppression of TSH secretion. In these patients, 
who represent over 80% of all thyroid cancer 
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patients, the goal of l-T4 treatment is to 
return TSH level to within the normal range 
(0.5–2.5 mU/l), and preferably at its lower end 
in young patients with a long life expectancy. 
Because the risk of persistent disease cannot be 
excluded, it seems safer to maintain serum TSH 
level below 0.5 mU/l, both from initial treatment 
until the 6–12 months’ follow-up appointment 
when assessment of complete remission can be 
undertaken. By contrast, patients with persis-
tent disease and those at high risk of recurrence 
require long-term TSH suppression, in partic-
ular when they are young and when they do 
not present with cardiovascular disease. In this 
group, the goal of l-T4 treatment is to reduce the 
serum TSH level to below 0.1 mU/l and maintain 
free-T3 level in the normal range (Figure 2).
TREATMENT WITH L-TETRAIODOTHYRONINE
Pharmacology
Exogenous l-T4 preparations should be close to 
100% pure, with less than 3% variation in l-T4 
content, because bioavailability might vary 
between preparations. To ensure optimal dosing, 
each patient should always receive the same 
prepara tion.42 l-T4 has a blood half-life of 
6–8 days, so a single daily dose is sufficient. Up 
to 80% of orally administered l-T4 is absorbed 
by the gut, with considerable interindividual 
variability.43 As food intake reduces l-T4 absorp-
tion, patients should be instructed to take their 
medication on an empty stomach, preferably in 
the morning, at least 20 minutes before break-
fast. Several substances—that is, cholestyramine, 
aluminum hydroxide, calcium carbonate, ferrous 
sulfate, and sucralfate—are known to interfere 
with intestinal absorption of l-T4.
44 Other 
substances can increase hepatic metabolism of 
l-T4 (e.g. the anticonvulsant drugs carbazepine, 
phenytoin, and phenobarbital), whereas estro-
gens can increase thyroid hormone requirements 
(by increasing serum levels of T4-binding glob-
ulin).45 All these possibilities should be consid-
ered when a patient on a presumably suppressive 
dose of l-T4 presents with an inappropriate 
serum TSH concentration. Chronic diseases 
such as regional enteritis, pancreatic disease, and 
cirrhosis can be associated with decreased l-T4 
absorption.44 Spurious elevations in serum TSH 
can also result from interference in the assay 
system by heterophilic antibodies.46
In patients with thyroid cancer, some authors 
have advocated the use of replacement doses of 
l-T4 together with tri-iodoacetic acid, a thyro-
mimetic drug that was originally believed to act 
exclusively at the pituitary level, without eliciting 
biologic activity in other tissues, to obtain 
complete TSH suppression without overt or 
subclinical thyrotoxicosis. It is now clear that tri-
iodo acetic acid does have effects on other tissues, 
and its use is no longer considered advisable.47,48
l-T3 alone is not indicated for long-term treat-
ment because of the widely varying serum levels 
that result from its administration. It is used only 
on a short-term basis preparatory to radioiodine 
administration.49 It might also be given with 
l-T4 for a few days, when the latter hormone is 
being resumed after a period of withdrawal, to 
restore euthyroidism more rapidly. The poten-
tial benefits of long-term therapy with both l-T3 
and l-T4 have yet to be established. It has been 
suggested that, for patients who have undergone 
total thyroidectomy, combined therapy can 
alleviate the sense of diminished wellbeing 
reported by many patients during treatment 
with l-T4 alone. The results of a prospective 
placebo-controlled double-blind clinical trial 
suggested that replacing part of the l-T4 dose 
with l-T3 improved quality of life,
50 but this 
effect was not confirmed in larger trials with 
different l-T4/l-T3 substitution regimens.
51–57
Dose
The dose of l-T4 should be carefully titrated to 
the individual needs of each patient. The dose 
required correlates roughly with body weight or 
(more accurately) with lean body mass. Athletes, 
in fact, require higher doses per kilogram of 
body weight than average, whereas lower doses 
High risk Low risk
Subclinical
hyperthyroidism
Subclinical
hypothyroidism
TSH (mU/l)
0.01 0.1 0.5 1.0 2.5
Before
assessment
of complete
remission
After
assessment
of complete
remission
Figure 2 Thyroid-stimulating hormone target level during treatment with 
L-tetraiodothyronine in high-risk and low-risk thyroid cancer patients. 
TSH, thyroid-stimulating hormone.
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are necessary for obese patients.58 The dose 
required to obtain low serum TSH levels after 
total thyroidectomy also decreases progressively 
with age (Table 1).59 Further dose reductions 
might be needed for subjects with concurrent 
heart disease.38
The adequacy of l-T4 therapy is verified by 
measuring serum TSH levels approximately 
3 months after the start of therapy. If the dose 
is appropriate, serum TSH levels will be around 
0.1 mU/l. To avoid the risk of iatrogenic thyro-
toxicosis, it is important to verify that the serum 
free T3 level is within the normal range, and that 
the serum free T4 level is around the upper limit 
of the normal range.6,7 Blood for measurement 
of free-T4 levels should be drawn after an over-
night fast and before patients take their daily 
dose of l-T4. Free-T4 levels are often as much 
as 25% higher when measured in specimens 
drawn within the first 3–4 h after the morning 
l-T4 dose.
If TSH is not low enough, or in case of thyro-
toxicosis, the daily dose of l-T4 is increased 
or decreased by 25 μg/kg, respectively, and 
hormone levels are rechecked 3 months later. 
Fine-tuning might require smaller adjustments, 
and the parameter to be considered is the total 
weekly dose of l-T4. Once the optimal dose has 
been defined, adjustments will be required only 
under particular circumstances (e.g. pregnancy, 
or significant weight gain or weight loss), and 
hormone levels can generally be rechecked once 
a year.
Thus l-T4 treatment is initiated after ablation 
and is controlled 3 months later. A complete 
follow-up evaluation is carried out between 6 
and 12 months after thyroid ablation. If it does 
not reveal any evidence of disease, TSH suppres-
sion is no longer necessary in low-risk patients, 
and the daily dose of l-T4 should be reduced 
until the TSH level is in the normal range.
Dose adjustments are often required during 
pregnancy. In women receiving l-T4 for replace-
ment alone, the dose should be increased by 
30% as soon as pregnancy is confirmed.60 In 
women receiving suppressive doses, hormone 
levels should be checked every month during 
pregnancy, and the l-T4 dose is increased if 
serum TSH level increases. When properly 
administered, l-T4 treatment does not affect the 
outcome of pregnancy and, conversely, preg-
nancy has no effect on the outcome of thyroid 
cancer. The prepregnancy dose of l-T4 should 
be resumed immediately after delivery.
Side effects of thyroid-stimulating 
hormone suppression
Concern has been expressed about the potentially 
detrimental effects of long-term suppressive 
l-T4 therapy on target organs.
38 The theoretical 
argument underlying this concern is that, even if 
free T3 and free T4 are maintained in the normal 
range, a TSH level below the lower limit of the 
normal range during l-T4 treatment implies a 
state of subclinical thyrotoxicosis.61 The bones 
and heart are considered to be the organs at 
highest risk.38
An analysis of available data obtained from 
women with subnormal TSH levels induced by 
l-T4 therapy revealed significant bone loss after 
menopause, but not before. There is no compel-
ling evidence for a higher incidence of fractures 
among women with a history of suppressive 
thyroid hormone therapy.38,62,63 In a prospec-
tive study with case-cohort sampling, an 
increased risk of fracture was reported in women 
over 65 years with low serum TSH levels,63 but 
this study did not distinguish between overt 
and subclinical thyrotoxicosis. Furthermore, 
several studies have failed to demonstrate any 
decrease in bone mass in patients who received 
long-term l-T4 treatment, and well-managed 
TSH-suppressive therapy does not contribute 
to osteopenia.64 These data suggest that TSH-
suppressive l-T4 therapy does not have a strong 
effect on the skeleton, but it might contribute 
to spontaneous postmenopausal bone loss.38 
Prophylactic therapy should thus be considered 
when a post menopausal patient must continue 
TSH suppression for cancer control.38
Even more controversial are the potentially 
adverse cardiac effects of long-term TSH 
suppression. Suppressive therapy with l-T4 has 
been associated with increased 24 h mean heart 
rates, with increased numbers of pre mature 
atrial beats in younger and middle-aged 
patients65 and with a higher incidence of atrial 
fibrillation in patients aged over 60 years.66 
Increased left-ventricular mass with a tendency 
Table 1 The dose of L-tetraiodothyronine required to obtain low serum 
thyroid-stimulating hormone levels in athyreotic patients.
Dose (μg/kg) Age
3–4 Children 
2.5–2.2 Adults 
1.4–1.2 Older adults 
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toward left-ventricular concentric remodeling 
has been reported in young and middle-aged 
patients with long-standing subclinical thyro-
toxicosis. These changes are often accompanied 
by impaired diastolic function and sometimes 
by decreased exercise performance and reduced 
systolic performance during exertion.67
The prognostic implications of these cardio-
vascular observations have yet to be clarified.38 
Elderly patients with endogenous subclinical 
thyrotoxicosis have been reported to have 
increased rates of cardiovascular mortality 
associated with increases in the left-ventricular 
mass, heart rate, and frequency of atrial arrhyth-
mias.37,38 Therefore, in patients with known 
heart disease and in older patients, the daily l-T4 
dose should also be carefully monitored.38 These 
subjects frequently complain of symptoms and 
signs of thyroid hormone excess (palpitations, 
heat intolerance, nervousness, and a feeling of 
reduced wellbeing) that impair their quality 
of life and their physical performance.68 If long-
term TSH suppression is necessary because of 
a high-risk cancer, a cardioselective β-blocking 
drug can be added to reduce the average heart 
rate and left-ventricular mass, and prevent 
supraventricular arrhythmias, thereby improving 
diastolic function, systolic performance during 
exercise, and quality of life.68
Acute hypothyroidism following withdrawal 
of L-tetraiodothyronine
Symptomatic hypothyroidism will occur when 
l-T4 is withdrawn 5 weeks prior to radioiodine 
scintigraphy or measurement of serum thyro-
globulin levels or both. To minimize the dura-
tion and severity of symptoms, l-T3 (which has 
a shorter half-life than l-T4) can be given for 
the first 3 weeks of l-T4 withdrawal. In this way, 
the interval of complete hormone withdrawal 
is reduced to the 2 weeks prior to testing. l-T4 
treatment is resumed immediately after the 
radioiodine treatment, and some physicians add 
T3 for the first 3–5 days to accelerate the return 
to euthyroidism.
The withdrawal of thyroid hormone therapy 
can be risky in certain cases. The acute hypo-
thyroidism caused by discontinuation of 
treatment might be associated with electro-
cardiogram abnormalities, reduced heart rate 
at rest and during exercise, increased systemic 
vascular resistance, reduced cardiac efficiency, 
and impaired left ventricular diastolic function 
and impaired systolic function during effort.69,70 
These effects might cause a deterioration of 
cardiac function in patients who are elderly 
and have known cardiac disease (arterial hyper-
tension, heart failure, coronary artery disease) 
or both. Moreover, the reduced renal clear-
ance associated with acute hypothyroidism can 
lead to overdose of drugs commonly used for 
cardiovascular disease, such as digoxin and anti-
arrhythmic drugs. The ordeal of l-T4 withdrawal 
can be avoided by using recombinant human 
TSH to stimulate radioiodine uptake and thyro-
globulin production. Recombinant human TSH 
is clinically safe and devoid of cardio vascular 
effects, and it is an efficient alternative to l-T4 
withdrawal for diagnostic procedures in patients 
with thyroid cancer.71
CONCLUSION
For the patient with thyroid cancer, l-T4 treat-
ment is a life-long prospect, and close moni-
toring is necessary to avoid adverse effects. For 
patients with papillary or follicular cancers, 
l-T4-induced suppression of TSH secretion is 
necessary only when there is evidence of persis-
tent or recurrent disease. In these cases, thyro-
toxicosis must be avoided, and l-T4 should be 
given at the lowest dose capable of producing 
target suppression levels. The vast majority of 
KEY POINTS
■ Thyroid-cell proliferation is thyroid-
stimulating hormone (TSH)-dependent, hence 
L-tetraiodothyronine (L-T4)-induced TSH 
suppression should be included in the treatment 
strategies for differentiated thyroid carcinomas
■ TSH suppression implies a state of subclinical 
thyrotoxicosis and becomes necessary only when 
there is evidence of persistent or recurrent disease; 
in low-risk patients, L-T4 treatment serves to return 
TSH level to within the normal range
■ To ensure optimal dosing, each patient must 
always receive the same preparation and the daily 
L-T4 dose should be carefully tailored
■ Adjustments of L-T4 dosage will be required 
under particular circumstances, for example in 
pregnant women, patients with significant weight 
gain or weight loss, those with known heart disease 
and older patients
■ If long-term TSH suppression is necessary 
because of a high-risk cancer, a cardioselective 
β-blocking drug can be added to reduce 
cardiovascular risk and to improve quality of life
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patients (those who have no evidence of disease 
after thyroidectomy) should be placed on l-T4 
therapy with the aim of maintaining serum TSH 
levels in the normal range.
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